Copyright
©The Author(s) 2022.
World J Gastrointest Surg. Oct 27, 2022; 14(10): 1120-1130
Published online Oct 27, 2022. doi: 10.4240/wjgs.v14.i10.1120
Published online Oct 27, 2022. doi: 10.4240/wjgs.v14.i10.1120
Table 1 Basic patient information and distribution of internal hemorrhoids
| Basic situation | Follow-up of 2020 (n = 201) | Follow-up of 2021 (n = 149) |
| Median follow-up | 33 (24-45) | 45 (34-57) |
| Age | 54.71 ± 13.016 | 54.77 ± 13.495 |
| Gender, n (%) | ||
| Male | 116 (57.7) | 92 (61.7) |
| Female | 85 (42.3) | 57 (38.3) |
| Hemorrhoids installment, n (%) | ||
| Stage Ⅰ | 88 (43.8) | 67 (45.0) |
| Stage Ⅱ | 53 (26.4) | 38 (25.5) |
| Stage Ⅲ | 50 (24.8) | 37 (24.8) |
| Stage Ⅳ | 10 (5.0) | 7 (4.7) |
Table 2 Long-term efficacy evaluation after cap-assisted endoscopic sclerotherapy treatment (follow-up in 2020, n = 201), n (%)
| Efficacy | Excellent | Good | Poor | χ2 | P value |
| Stage Ⅰ | 54 (61.4) | 26 (29.5) | 8 (9.1) | ||
| Stage Ⅱ | 35 (66.1) | 13(24.5) | 5 (9.4) | 8.90 | 0.177 |
| Stage Ⅲ | 34 (68.0) | 13 (26.0) | 3 (6.0) | ||
| Stage Ⅳ | 3 (30.0) | 3 (30.0) | 4 (40.0) |
Table 3 Long-term efficacy evaluation after cap-assisted endoscopic sclerotherapy treatment (follow-up in 2021, n = 149), n (%)
| Efficacy | Excellent | Good | Poor | χ2 | P value |
| Stage Ⅰ | 46 (68.6) | 18 (26.9) | 3 (4.5) | ||
| Stage Ⅱ | 22 (57.9) | 13(34.2) | 3 (7.9) | 4.78 | 0.572 |
| Stage Ⅲ | 20 (54.1) | 16 (43.2) | 1 (2.7) | ||
| Stage Ⅳ | 4 (57.1) | 3 (42.9) | 0 (0) |
- Citation: Xie YT, Yuan Y, Zhou HM, Liu T, Wu LH, He XX. Long-term efficacy and safety of cap-assisted endoscopic sclerotherapy with long injection needle for internal hemorrhoids. World J Gastrointest Surg 2022; 14(10): 1120-1130
- URL: https://www.wjgnet.com/1948-9366/full/v14/i10/1120.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v14.i10.1120